FDA Approves Rolapitant for Prevention of Nausea and Vomiting from Chemo

September 5, 2015

The U.S. Food and Drug Administration (FDA) approved rolapitant to prevent chemo-induced nausea and vomiting. Nausea and vomiting is a common side effect for many cancer survivors receiving chemotherapy. Aside from affecting quality of life, prolonged nausea and vomiting can lead to weight loss and malnourishment which may lead to treatment delays, possibly making treatment less effective. Read more here.

If you are a cancer survivor struggling with treatment-induced nausea and vomiting, visit My PearlPoint to learn nutrition tips and strategies to help manage nausea